1. The Development of Peptide-Based Tools for the Analysis of Angiogenesis
- Author
-
Jan Marik, Annie Ogasawara, Simon-P. Williams, Anna V. Fedorova, Alexander N. Vanderbilt, Kurt Deshayes, Christian Wiesmann, Herman Gill, Ping Wu, Judith E. Flores, Jeremy Murray, Jeff N. Tinianow, Y. Gloria Meng, and Kerry Zobel
- Subjects
Phage display ,Angiogenesis ,Clinical Biochemistry ,Peptide ,Biochemistry ,chemistry.chemical_compound ,Text mining ,Drug Discovery ,medicine ,Molecular Biology ,Pharmacology ,chemistry.chemical_classification ,biology ,medicine.diagnostic_test ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Vascular endothelial growth factor ,chemistry ,Positron emission tomography ,Immunology ,biology.protein ,Cancer research ,Molecular Medicine ,Antibody ,business - Abstract
Summary Limitations to the application of molecularly targeted cancer therapies are the inability to accurately match patient with effective treatment and the absence of a prompt readout of posttreatment response. Noninvasive agents that rapidly report vascular endothelial growth factor (VEGF) levels using positron emission tomography (PET) have the potential to enhance anti-angiogenesis therapies. Using phage display, two distinct classes of peptides were identified that bind to VEGF with nanomolar affinity and high selectivity. Co-crystal structures of these different peptide classes demonstrate that both bind to the receptor-binding region of VEGF. 18 F-radiolabelling of these peptides facilitated the acquisition of PET images of tumor VEGF levels in a HM7 xenograph model. The images obtained from one 59-residue probe, 18 F-Z-3B, 2 hr postinjection are comparable to those obtained with anti-VEGF antibody B20 72 hr postinjection. Furthermore, VEGF levels in growing SKOV3 tumors were followed using 18 F-Z-3B as a PET probe with VEGF levels increasing with tumor size.
- Published
- 2011
- Full Text
- View/download PDF